<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs
Image Overlay - Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs

Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs

Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs

The Institute for Clinical and Economic Review has published a draft report on the cost-effectiveness of three soon to be launched migraine drugs. ICER used expected pricing numbers in its evaluation and found that triptans would “provide a greater benefit at a lower total cost” for patients who respond to them, however, the new drugs would benefit those that do not respond to the existing treatments. As the only integrated premium courier service provider, Yourway supports new drug development and relies on our team of highly experienced project managers to oversee supply chain management worldwide.

Back to Index
Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit (Munich)

April 15-16, 2024
Science Congress Center Munich

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Media

Articles

The At-home Trial Experience: Leveraging value-chain to reach and retain patients

Open chat
Come chat with us!
Hello! How can I help you?